A Case Series of HIV-Seropositive Patients and Hypercoagulable State—Is It Difficult to Treat Even with Therapeutic Anticoagulation?

 

 Buy Article Permissions and Reprints

Abstract

Patients with human immunodeficiency virus (HIV) are at risk of developing thrombosis and are 8 to 10 times more likely to develop thrombosis than the general population. Moreover, if they have hypercoagulable state they can have severe thrombosis and life-threatening thrombotic events. The purpose of this retrospective study is to analyze hypercoagulable state in HIV-seropositive patients who have been diagnosed with venous thromboembolism (VTE). This study is a subgroup study of a larger cohort group of HIV-seropositive patients with VTE followed up with our vascular medicine outpatient clinic. The patients included for this study were HIV-seropositive patients with hypercoagulable state, analyzed over the past 3 years, and followed prospectively. HIV-seropositive patients with arterial thrombosis were excluded. These patients had minimum, regular follow-up of 3 months, with a Doppler scan in the beginning and last follow-up. All the patients were analyzed for hypercoagulable state and the patients selected in this study were those who were tested positive for hypercoagulable state. All patients were analyzed for age, gender, race, site of thrombosis, coagulation factors, lipid panel, type of antiretroviral treatment, past or present history of infections or malignancy, CD4 absolute and helper cell counts at the beginning of thrombosis, and response to treatment and outcome. Patients with HIV with arterial thrombosis were excluded. The study was approved by the ethics committee. Five patients were included in this study. The mean age was 47.8 years (range 38 to 58 years). All were male patients with lower limb thrombosis. Most common venous thrombosis was popliteal vein thrombosis, followed by common femoral, superficial femoral, and external iliac thrombosis. Two patients had deficiency of protein S, two had high homocysteine levels, one had deficiency of antithrombin 3, and one had increase in anticardiolipin immunoglobulin G antibody. All the patients were taking nucleoside and nonnucleoside inhibitors but only one patient was taking protease inhibitors. There was no history of malignancy but two patients had past history of tuberculosis. The mean absolute CD4 counts were 244 cells/UL (range 103 to 392 cells/UL) and helper CD4 counts were 19.6 cells/UL (range 15 to 30 cells/UL). All were anticoagulated with warfarin or enoxaparin. There was complete resolution of deep vein thrombosis only in one patient on long-term anticoagulation but there was no resolution of thrombosis in the other four patients despite of therapeutic anticoagulation for more than 6 months. All the patients are alive and on regular follow-up. Thrombosis in HIV patients is seen more commonly in middle aged, community ambulant male patients. The most common hypercoagulable state was noted as deficiency of protein S and hyperhomocysteinemia. Eighty percent of the patients did not respond to therapeutic anticoagulation.

• References

• 1 Bibas M, Biava G, Antinori A. HIV-associated venous thromboembolism. Mediterr J Hematol Infect Dis 2011; 3 (1) e2011030
  CrossrefPubMedGoogle Scholar
• 2 Ahonkhai AA, Gebo KA, Streiff MB, Moore RD, Segal JB. Venous thromboembolism in patients with HIV/AIDS: a case-control study. J Acquir Immune Defic Syndr 2008; 48 (3) 310-314
  CrossrefPubMedGoogle Scholar
• 3 Klein SK, Slim EJ, de Kruif MD , et al. Is chronic HIV infection associated with venous thrombotic disease? A systematic review. Neth J Med 2005; 63: 129-136
  PubMedGoogle Scholar
• 4 Saif MW, Greenberg B. HIV and thrombosis: a review. AIDS Patient Care STDS 2001; 15 (1) 15-24
  CrossrefPubMedGoogle Scholar
• 5 Jacobson MC, Dezube BJ, Aboulafia DM. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. Oxford Journals. Clin Infect Dis 2004; 39 (8) 1214-1222
  CrossrefPubMedGoogle Scholar
• 6 Shen Y-M, Frenkel EP. Thrombosis and a hypercoagulable state in HIV-infected patients. Clin Appl Thromb Hemost 2004; 10 (3) 277-280
  CrossrefPubMedGoogle Scholar
• 7 Orlovic D, Smego A. Hypercoagulability due to protein S deficiency in HIV-seropositive patients. RA Int J Collab Res Intern Med Public Health 2009; 1 (6–7) 187-193
  PubMedGoogle Scholar
• 8 Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81 (7) 1801-1807
  PubMedGoogle Scholar
• 9 Erbe M, Rickerts V, Bauersachs RM, Lindhoff-Last E. Acquired protein C and protein S deficiency in HIV-infected patients. Clin Appl Thromb Hemost 2003; 9 (4) 325-331
  CrossrefPubMedGoogle Scholar
• 10 Parruti G, Manzoli L, Di Iorio G , et al. Plasma homocysteine levels in an Italian cohort of HIV infected patients. International AIDS society 2012; The 3rd IAS Conference on HIV Pathogenesis and Treatment. Abstract no. 2177530.
  PubMedGoogle Scholar